- Home
- ATAI vs TLRY Comparison
ATAI vs TLRY Comparison
Compare ATAI & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAI | TLRY |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Netherlands | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ATAI | TLRY |
|---|---|---|
| Price | $3.99 | $9.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $14.33 | ★ $150.00 |
| AVG Volume (30 Days) | 3.2M | ★ 20.1M |
| Earning Date | 11-12-2025 | 01-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,018,000.00 | ★ $830,766,000.00 |
| Revenue This Year | $943.18 | $7.28 |
| Revenue Next Year | N/A | $4.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 811.78 | 2.31 |
| 52 Week Low | $1.15 | $3.51 |
| 52 Week High | $6.75 | $23.20 |
Technical Indicators
Market Signals| Indicator | ATAI | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 56.03 |
| Support Level | $3.88 | $9.82 |
| Resistance Level | $4.72 | $15.70 |
| Average True Range (ATR) | 0.24 | 1.47 |
| MACD | 0.01 | -0.45 |
| Stochastic Oscillator | 13.10 | 15.61 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.